DrugPatentWatch Database Preview
Tris Pharma Inc Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for TRIS PHARMA INC, and when can generic versions of TRIS PHARMA INC drugs launch?
TRIS PHARMA INC has twenty-four approved drugs.
There are six US patents protecting TRIS PHARMA INC drugs.
There are nineteen patent family members on TRIS PHARMA INC drugs in fourteen countries and twenty-three supplementary protection certificates in nine countries.
Summary for Tris Pharma Inc
| International Patents: | 19 |
| US Patents: | 6 |
| Tradenames: | 23 |
| Ingredients: | 22 |
| NDAs: | 24 |
| Drug Master File Entries: | 6 |
| Patent Litigation for Tris Pharma Inc: | See patent lawsuits for Tris Pharma Inc |
Drugs and US Patents for Tris Pharma Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tris Pharma Inc | PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE | dextromethorphan hydrobromide; promethazine hydrochloride | SYRUP;ORAL | 091687-001 | Jun 28, 2012 | DISCN | No | No | Start Trial | Start Trial | |||||
| Tris Pharma Inc | GABAPENTIN | gabapentin | SOLUTION;ORAL | 091286-001 | Mar 14, 2016 | AA | RX | No | No | Start Trial | Start Trial | ||||
| Tris Pharma Inc | DYANAVEL XR | amphetamine | SUSPENSION, EXTENDED RELEASE;ORAL | 208147-001 | Oct 19, 2015 | RX | Yes | Yes | 10,086,087 | Start Trial | Y | Start Trial | |||
| Tris Pharma Inc | DYANAVEL XR | amphetamine | SUSPENSION, EXTENDED RELEASE;ORAL | 208147-001 | Oct 19, 2015 | RX | Yes | Yes | 8,747,902 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Tris Pharma Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Brazil | PI0709606 | Start Trial |
| South Korea | 101495146 | Start Trial |
| Russian Federation | 2008140944 | Start Trial |
| Russian Federation | 2435569 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Tris Pharma Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0162036 | 2000C/032 | Belgium | Start Trial | PRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329 |
| 1539166 | SPC/GB13/070 | United Kingdom | Start Trial | PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. Q; REGISTERED: UK EU/1/13/833 20130626 |
| 1499331 | SPC/GB13/034 | United Kingdom | Start Trial | PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313 |
| 1539166 | 92323 | Luxembourg | Start Trial | PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
